NCT06628778View on ClinicalTrials.gov

Collaborative Risk-stratified Investigation in Teen Inpatients With Critical Illness: Anticoagulation With LMWH in Kids for ThromboProphylaxis (CRITICAL-Kids-TP)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

802

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2030

Conditions
Venous Thromboembolism (VTE)
Interventions
DRUG

Dalteparin

Dalteparin thromboprophylaxis administered subcutaneously twice daily (every 12 hours) from enrollment through pediatric intensive care unit discharge

Trial Locations (1)

33704

"Johns Hopkins All Childrens Hospital", St. Petersburg

All Listed Sponsors
collaborator

University of California, San Diego

OTHER

lead

Johns Hopkins All Children's Hospital

OTHER